Medscape |
Reslizumab Works Best in Late-Onset Eosinophilic Asthma
Medscape AMSTERDAM — In patients with late-onset asthma who have elevated blood eosinophils, the anti-interleukin 5 (IL-5) antibody reslizumab can reduce exacerbations by 75% compared with placebo, according to a new analysis of data from two phase 3 trials … Teva Presents New Reslizumab Data at European Respiratory Society (ERS … |
View full post on asthma – Google News